Divalproex Sodium Tablet, Delayed Release
Product Images NDC 72789-354

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 72789-354). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789354 Label (72789354)

Label for Divalproex Sodium delayed-release tablets, USP 500 mg by PD-Rx Pharmaceuticals, Inc. The label states valproic acid activity, contains 100 tablets, and is for Rx only. It includes storage instructions, barcode, manufacturer information (Sun Pharmaceutical Industries Ltd, India), and a medication guide URL with a QR code.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A vertical bar chart labeled Figure 1 comparing response rates (%) between placebo (PBO) and Divalproex Sodium (DVPX) in two studies. Study 1 (YMRS) shows 26% response for placebo and 60% for Divalproex Sodium. Study 2 (MRS) shows 29% response for placebo and 58% for Divalproex Sodium. Percentages are displayed above the bars.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A line graph comparing the percentage of patients with reductions in CPS rate between Divalproex Sodium (DVPX) and placebo groups. The y-axis shows % reduction in CPS rate from -100% to 100%, indicating worsening or improvement. The x-axis represents the percentage of patients from 100% to 0%. The graph illustrates trends in response rates between treatment and placebo groups.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

Figure 3 is a cumulative percentage graph showing percent reduction in CPS Rate on the vertical axis versus percent of patients on the horizontal axis. Two lines compare high dose and low dose groups, with improvement indicated upward and worsening downward along the vertical axis.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Mean 4-week Migraine Rates' compares migraine rates over two studies. The x-axis represents two studies (Study 1 and Study 2) each with bars for Placebo and Divalproex Sodium (DVPX). The y-axis shows migraine rates ranging from 0 to 6. In both studies, migraine rates are higher with Placebo compared to DVPX.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure diagram of Divalproex Sodium, showing the molecular arrangement of its components including sodium ion and carboxylate groups in a polymeric form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.